995 related articles for article (PubMed ID: 26883357)
21. Nr5a2 heterozygosity sensitises to, and cooperates with, inflammation in KRas(G12V)-driven pancreatic tumourigenesis.
Flandez M; Cendrowski J; Cañamero M; Salas A; del Pozo N; Schoonjans K; Real FX
Gut; 2014 Apr; 63(4):647-55. PubMed ID: 23598351
[TBL] [Abstract][Full Text] [Related]
22. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract][Full Text] [Related]
23. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
24. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
[TBL] [Abstract][Full Text] [Related]
25. A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.
Yamaguchi T; Ikehara S; Nakanishi H; Ikehara Y
J Pathol; 2014 Oct; 234(2):228-38. PubMed ID: 25042889
[TBL] [Abstract][Full Text] [Related]
26. The Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment.
Sun H; Zhang B; Li H
Technol Cancer Res Treat; 2020; 19():1533033820920969. PubMed ID: 32372692
[TBL] [Abstract][Full Text] [Related]
27. KRAS mutations in pancreatic circulating tumor cells: a pilot study.
Kulemann B; Liss AS; Warshaw AL; Seifert S; Bronsert P; Glatz T; Pitman MB; Hoeppner J
Tumour Biol; 2016 Jun; 37(6):7547-54. PubMed ID: 26684803
[TBL] [Abstract][Full Text] [Related]
28. Concentrations of trace elements and KRAS mutations in pancreatic ductal adenocarcinoma.
Gómez-Tomás Á; Pumarega J; Alguacil J; Amaral AFS; Malats N; Pallarès N; Gasull M; Porta M;
Environ Mol Mutagen; 2019 Oct; 60(8):693-703. PubMed ID: 31066938
[TBL] [Abstract][Full Text] [Related]
29. Overall survival of pancreatic ductal adenocarcinoma is doubled by
Lee JS; Lee H; Woo SM; Jang H; Jeon Y; Kim HY; Song J; Lee WJ; Hong EK; Park SJ; Han SS; Kim SY
Theranostics; 2021; 11(7):3472-3488. PubMed ID: 33537098
[No Abstract] [Full Text] [Related]
30. Long noncoding RNA TP53TG1 promotes pancreatic ductal adenocarcinoma development by acting as a molecular sponge of microRNA-96.
Zhang Y; Yang H; Du Y; Liu P; Zhang J; Li Y; Shen H; Xing L; Xue X; Chen J; Zhang X
Cancer Sci; 2019 Sep; 110(9):2760-2772. PubMed ID: 31325400
[TBL] [Abstract][Full Text] [Related]
31. KRAS-related proteins in pancreatic cancer.
Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
[TBL] [Abstract][Full Text] [Related]
32. It Takes a Village to Overcome KRAS Dependence in Pancreatic Cancer.
Carr RM; Fernandez-Zapico ME
Cancer Discov; 2020 Jul; 10(7):910-912. PubMed ID: 32611735
[TBL] [Abstract][Full Text] [Related]
33. Targeting Defects in the Cellular DNA Damage Response for the Treatment of Pancreatic Ductal Adenocarcinoma.
Schmitt A; Feldmann G; Zander T; Reinhardt HC
Oncol Res Treat; 2018; 41(10):619-625. PubMed ID: 30286473
[TBL] [Abstract][Full Text] [Related]
34. Deregulation of the MiR-193b-KRAS Axis Contributes to Impaired Cell Growth in Pancreatic Cancer.
Jin X; Sun Y; Yang H; Li J; Yu S; Chang X; Lu Z; Chen J
PLoS One; 2015; 10(4):e0125515. PubMed ID: 25905463
[TBL] [Abstract][Full Text] [Related]
35. Hypoxia and pancreatic ductal adenocarcinoma.
Yamasaki A; Yanai K; Onishi H
Cancer Lett; 2020 Aug; 484():9-15. PubMed ID: 32380129
[TBL] [Abstract][Full Text] [Related]
36. Crosstalk between miRNAs and signaling pathways involved in pancreatic cancer and pancreatic ductal adenocarcinoma.
Lotfi Z; Najjary S; Lotfi F; Amini M; Baghbanzadeh A; Rashid DJ; Asl ER; Baradaran B; Mokhtarzadeh A
Eur J Pharmacol; 2021 Jun; 901():174006. PubMed ID: 33711308
[TBL] [Abstract][Full Text] [Related]
37. Oncogenic KRAS Induces NIX-Mediated Mitophagy to Promote Pancreatic Cancer.
Humpton TJ; Alagesan B; DeNicola GM; Lu D; Yordanov GN; Leonhardt CS; Yao MA; Alagesan P; Zaatari MN; Park Y; Skepper JN; Macleod KF; Perez-Mancera PA; Murphy MP; Evan GI; Vousden KH; Tuveson DA
Cancer Discov; 2019 Sep; 9(9):1268-1287. PubMed ID: 31263025
[TBL] [Abstract][Full Text] [Related]
38. Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice.
Kopp JL; Dubois CL; Schaeffer DF; Samani A; Taghizadeh F; Cowan RW; Rhim AD; Stiles BL; Valasek M; Sander M
Gastroenterology; 2018 Apr; 154(5):1509-1523.e5. PubMed ID: 29273451
[TBL] [Abstract][Full Text] [Related]
39. Energy metabolism and proliferation in pancreatic carcinogenesis.
Regel I; Kong B; Raulefs S; Erkan M; Michalski CW; Hartel M; Kleeff J
Langenbecks Arch Surg; 2012 Apr; 397(4):507-12. PubMed ID: 22430298
[TBL] [Abstract][Full Text] [Related]
40. PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells.
Liang C; Shi S; Liu M; Qin Y; Meng Q; Hua J; Ji S; Zhang Y; Yang J; Xu J; Ni Q; Li M; Yu X
Cancer Res; 2019 Jan; 79(1):133-145. PubMed ID: 30355620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]